US-listed I-Mab readies Shanghai IPO
Chinese biopharmaceutical company I-Mab is moving ahead with plans for a dual listing in Shanghai, as it looks to broaden its investor base.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: